Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

December 18th 2019

December 18th, 2019

Cycle Pharmaceuticals (Cycle) is pleased to announce that it has signed an agreement with Baylor Genetics (Baylor) to support succinylacetone (SA) testing for hereditary tyrosinemia type 1 (HT-1) patients at Texas Children’s Hospital.

This partnership will help the ongoing monitoring of HT-1 patients, where accurate SA testing is essential to manage treatment. Dr V. Reid Sutton, Medical Director of Biochemical Genetics at Baylor said “Individuals with rare diseases often struggle in obtaining medications and with access to diagnostic testing. In the management of tyrosinemia, while the medication is lifesaving, regular assessment of tyrosine and succinylacetone is essential to ensuring the best outcome for patients. I am incredibly grateful to Cycle Pharmaceuticals for their commitment ensuring that those with tyrosinemia have reliable access to medication and diagnostic testing to ensure optimal management of their disease”

Cycle is committed to changing the way that HT-1 is treated and managed around the world. Cycle has worked for years with the US Food and Drug Administration (FDA), physicians and patient groups to reduce the impact that HT-1 treatment has on patients’ lives.

Chris Abbott, National Account Manager at Cycle said, “Baylor is a leading pioneer in genetic testing and has access to world-renowned experts. This cooperation between Cycle and Baylor reflects Cycle’s spirit and willingness to help patients, as well as the healthcare providers that take care of them”.

With Headquarters in Cambridge, U.K. and offices in Boston, Mass. (USA), Cycle has developed unique partnerships with renowned universities and companies around the world. For further information, please visit www.cyclepharma.com

GL-0031 Date of Preparation: Nov 2019